Tumor Genetics Offer a Path Toward More Personalized Lung Cancer Immunotherapy
en-GBde-DEes-ESfr-FR

Tumor Genetics Offer a Path Toward More Personalized Lung Cancer Immunotherapy

17/11/2026 Compuscript Ltd

A new review in Genes & Diseases highlights how the genetic makeup of lung tumors and their surrounding immune environment can help explain why immunotherapy works well for some patients but offers limited benefit to others. The article outlines opportunities to make treatment selection more precise for non-small cell lung cancer (NSCLC).

Prepared by a team at the First Hospital of Jilin University, the review brings together evidence on cancer-driving mutations and cellular signaling pathways that influence responses to immune checkpoint inhibitors. These medicines release molecular brakes on immune cells, helping them recognize and attack cancer. However, tumors can develop ways to evade this response.

The central message is that tumor genetics and immune characteristics should be considered together. Measuring PD-L1, a protein associated with immunotherapy response, provides useful information, but a broader assessment can reveal important differences hidden behind a single biomarker result. Genetic sequencing and immune profiling could support more individualized treatment decisions.

Among the genetic changes discussed, certain KRAS mutations, particularly when accompanied by TP53 mutations, are associated with greater immunotherapy benefit. By contrast, common EGFR mutations and ALK rearrangements often show limited responses to checkpoint inhibitors used alone. Other alterations, including STK11 and KEAP1, can contribute to an immune environment that resists treatment, underscoring the importance of examining combinations of mutations.

The review also explores strategies to reshape the tumor microenvironment, the network of immune cells, supporting cells and molecules surrounding a tumor. Blocking the CD73/adenosine pathway could help reduce immune suppression, while activating STING signaling may strengthen immune recognition. Approaches involving DNA damage repair and other signaling networks offer additional possibilities for improving responses to checkpoint blockade.

Combining immunotherapy with targeted medicines or chemotherapy may offer advantages in selected settings. However, the article emphasizes that combinations require careful evaluation: some pairings can cause substantial liver toxicity or lung inflammation. Potential benefit therefore needs to be balanced against treatment risks, mutation subtype and previous therapy.

For patients whose cancer stops responding, the review proposes repeat genetic and biomarker assessment to help identify changes that could inform subsequent treatment choices. Several emerging combinations remain experimental, and their value requires further clinical validation.
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 10.4 |Impact Factor:14.6
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)
# # # # # #
Reference
Chunyan Liu, Shan Zhu, Jing Wu, Yuan Qiao, Ning Yang, Jingtao Chen, Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC, Genes & Diseases, Volume 14, Issue 1, 2027, 102230, https://doi.org/10.1016/j.gendis.2026.102230

Funding
National Key Research and Development Program (China) 2021YFF0704800
National Natural Science Foundation of China 82273186
National Natural Science Foundation of China 82102714
Scientific and Technological Developing Plan of Jilin Province (China) YDZJ202201ZYTS098
Jilin Provincial Department of Education Scientific Research Project (China) JJKH20231213KJ
Jilin Provincial Specialized Fund for Medical and Health Talents (China) JLSWSRCZX2023-111
Chunyan Liu, Shan Zhu, Jing Wu, Yuan Qiao, Ning Yang, Jingtao Chen, Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC, Genes & Diseases, Volume 14, Issue 1, 2027, 102230, https://doi.org/10.1016/j.gendis.2026.102230
Attached files
  • Tumor microenvironment features of distinct oncogenic mutation subtypes in NSCLC.
  • CD73 in NSCLC affects the function of different immune cells in the tumor microenvironment.
  • CAFs highly express CD73 and interact with T cells and tumor cells in NSCLC.
17/11/2026 Compuscript Ltd
Regions: Europe, Ireland, Asia, China
Keywords: Science, Life Sciences, Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by AlphaGalileo Terms Of Use Privacy Statement